Saturday 17 October 2026
Export TECH’s income statement to Excel — free account
Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.
72.54
0.02
+0.03%
Follow TECH
Bio-Techne Corp 8-K filed Jun 25, 2026
7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits